German medical technology company Biotronik has launched its Inventra HF-T implantable cardioverter defibrillator (ICD) in the US.
The device has been designed as a cardiac resynchronisation therapy defibrillator (CRT-D) to deliver ultra-high-energy measuring 42 joules (J) on the first shock to heart failure patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
An ICD is considered necessary for patients suffering from tachycardia (fast arrhythmias) which converts dangerous arrhythmias to a normal heart rhythm by triggering shocks to the heart.
Jersey Shore University Medical Center electrophysiologist Dr Mark Mascarenhas said: "For an increasing number of patients specifically those with larger cardiac anatomy and lower ejection fraction a shock that is higher than the standard 36-37 J may be needed to convert irregular arrhythmia.
"The sooner an effective shock can be delivered, the likelihood of survival increases for these patients.
“For such patients, a CRT-D that delivers ultra-high energy on the first shock has a higher chance of converting the irregular arrhythmia.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"With the availability of Inventra HF-T, more heart failure patients will be able to receive 42J energy delivered upon the first shock and, hence, receive life-saving therapy."
The new device is part of the Inventra 7 CRT-D series featuring Biotronik Home Monitoring, ProMRI, CLS, 45 J ultra-high energy and quadripolar LV pacing enabling multiple left-ventricular pacing and sensing configurations for CRT management, thereby offering a powerful therapy for patients at risk of high defibrillation thresholds (DFTs).
Image: Biotronik’s Inventra HF-T CRT device. Photo: courtesy of Biotronik.
